{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T13:24:16Z","timestamp":1762608256648,"version":"build-2065373602"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006264","name":"Rikagaku Kenkyujo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.eplepsyres.2021.106614","type":"journal-article","created":{"date-parts":[[2021,3,12]],"date-time":"2021-03-12T02:36:23Z","timestamp":1615516583000},"page":"106614","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children\u2019s hospital in Japan: A retrospective observational cohort study"],"prefix":"10.1016","volume":"173","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-2401","authenticated-orcid":false,"given":"Keiko","family":"Hikino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumi","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6221-2189","authenticated-orcid":false,"given":"Takeshi","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4139-8794","authenticated-orcid":false,"given":"Taisei","family":"Mushiroda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0005","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/RHU.0b013e31817a241a","article-title":"Drug allergies may be more frequent in systemic lupus erythematosus than in rheumatoid arthritis","volume":"14","author":"Aceves-Avila","year":"2008","journal-title":"J. Clin. Rheumatol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2021.106614_bib0010","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/j.1528-1167.2007.01109.x","article-title":"Rash from antiepileptic drugs: influence by gender, age, and learning disability","volume":"48","author":"Alvestad","year":"2007","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-008298","article-title":"A prospective study of adverse drug reactions to antiepileptic drugs in children","volume":"5","author":"Anderson","year":"2015","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.eplepsyres.2021.106614_bib0020","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.seizure.2012.06.013","article-title":"Self reported adverse effects of mono and polytherapy for epilepsy","volume":"21","author":"Andrew","year":"2012","journal-title":"Seizure"},{"issue":"20","key":"10.1016\/j.eplepsyres.2021.106614_bib0025","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1212\/01.wnl.0000261917.83337.db","article-title":"Comparison and predictors of rash associated with 15 antiepileptic drugs","volume":"68","author":"Arif","year":"2007","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.eplepsyres.2021.106614_bib0030","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1007\/s00228-016-2092-3","article-title":"Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders-a pharmacoepidemiological study and clinical implications","volume":"72","author":"Baftiu","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.eplepsyres.2021.106614_bib0035","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s00228-019-02678-1","article-title":"Safety aspects of antiepileptic drugs-a population-based study of adverse effects relative to changes in utilisation","volume":"75","author":"Baftiu","year":"2019","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106614_bib0040","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/cpt.598","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron","volume":"102","author":"Bell","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/clpt.2014.159","article-title":"Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing","volume":"96","author":"Caudle","year":"2014","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3389\/fphar.2020.00969","article-title":"Pharmacogenetic testing for prevention of severe cutaneous adverse drug reactions","volume":"11","author":"Chang","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0055","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106614_bib0060","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.ejpn.2017.02.003","article-title":"Psychiatric and behavioral side effects of anti-epileptic drugs in adolescents and children with epilepsy","volume":"21","author":"Chen","year":"2017","journal-title":"Eur. J. Paediatr. Neurol."},{"issue":"1","key":"10.1016\/j.eplepsyres.2021.106614_bib0065","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40360-019-0285-y","article-title":"Adverse drug reactions associated with six commonly used antiepileptic drugs in southern China from 2003 to 2015","volume":"20","author":"Du","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0070","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.seizure.2018.01.018","article-title":"Safety of antiepileptic drugs in children and young people: a prospective cohort study","volume":"56","author":"Egunsola","year":"2018","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106614_bib0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042098611411127","article-title":"New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety?","volume":"2","author":"French","year":"2011","journal-title":"Ther. Adv. Drug Saf."},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0080","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1002\/cpt.1319","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes","volume":"105","author":"Gonsalves","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.eplepsyres.2021.106614_bib0085","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/epi.13946","article-title":"Antiepileptic drug behavioral side effects and baseline hyperactivity in children and adolescents with new onset epilepsy","volume":"59","author":"Guilfoyle","year":"2018","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0090","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/j.jaip.2018.02.018","article-title":"The frequency and clinical features of hypersensitivity reactions to antiepileptic drugs in children: a prospective study","volume":"6","author":"Guvenir","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0095","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/cpt.1706","article-title":"HLA-B*51:01 and CYP2C9*3 are risk factors for phenytoin-induced eruption in the Japanese population: analysis of data from the Biobank Japan Project","volume":"107","author":"Hikino","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106614_bib0100","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40261-019-00754-z","article-title":"Adverse cutaneous drug reactions associated with old- and new- generation antiepileptic drugs using the Japanese pharmacovigilance database","volume":"39","author":"Hosohata","year":"2019","journal-title":"Clin. Drug Investig."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106614_bib0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0110","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/jcpt.13001","article-title":"Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: subgroup analysis based on a Japanese spontaneous database","volume":"44","author":"Inada","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106445","article-title":"Prescription patterns of antiepileptic drugs in Kazakhstan in 2018: a retrospective study of 57,959 patients","volume":"99","author":"Jacob","year":"2019","journal-title":"Epilepsy Behav."},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106614_bib0120","first-page":"89","article-title":"a study on drug prescription pattern of Antiepileptic Drugs (AEDs) at a tertiary care hospital in North Eastern India","volume":"68","author":"Jenibemo","year":"2020","journal-title":"J. Assoc. Physicians India"},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106614_bib0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","article-title":"Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: monotherapy versus polytherapy","volume":"145","author":"Joshi","year":"2017","journal-title":"Indian J. Med. Res."},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106614_bib0130","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jclinepi.2012.09.016","article-title":"Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity","volume":"66","author":"Kim","year":"2013","journal-title":"J. Clin. Epidemiol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106614_bib0135","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.3346\/jkms.2020.35.e17","article-title":"Adverse skin reactions with antiepileptic drugs using Korea adverse event reporting system database, 2008-2017","volume":"35","author":"Kim","year":"2020","journal-title":"J. Korean Med. Sci."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.yebeh.2015.11.009","article-title":"Specific adverse effects of antiepileptic drugs--a true-to-life monotherapy study","volume":"54","author":"Kowski","year":"2016","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0145","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jaip.2018.07.003","article-title":"Hypersensitivity reactions to antiepileptic drugs in children: epidemiologic, pathogenetic, clinical, and diagnostic aspects","volume":"6","author":"Kuyucu","year":"2018","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106614_bib0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.14581\/jer.14010","article-title":"Old versus new: why do we need new antiepileptic drugs?","volume":"4","author":"Lee","year":"2014","journal-title":"J. Epilepsy Res."},{"issue":"12","key":"10.1016\/j.eplepsyres.2021.106614_bib0155","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMoa1013297","article-title":"HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans","volume":"364","author":"McCormack","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.eplepsyres.2017.11.007","article-title":"Meta-analyses of newer antiepileptic drugs as adjunct for treatment of focal epilepsy in children","volume":"139","author":"Mohd-Tahir","year":"2018","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0165","article-title":"Delayed hypersensitivity to antiepileptic drugs in children","author":"Mori","year":"2020","journal-title":"Pediatr. Allergy Immunol."},{"issue":"7","key":"10.1016\/j.eplepsyres.2021.106614_bib0170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamaneurol.2018.0278","article-title":"Association of HLA-A*31:01 screening with the incidence of carbamazepine-induced cutaneous adverse reactions in a Japanese population","volume":"75","author":"Mushiroda","year":"2018","journal-title":"JAMA Neurol."},{"issue":"14","key":"10.1016\/j.eplepsyres.2021.106614_bib0175","first-page":"2732","article-title":"Spontaneous reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with antiepileptic drugs","volume":"19","author":"Ordonez","year":"2015","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/hmg\/ddq537","article-title":"Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population","volume":"20","author":"Ozeki","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0185","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1474-4422(03)00409-5","article-title":"Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0190","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"issue":"9","key":"10.1016\/j.eplepsyres.2021.106614_bib0195","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1016\/j.eplepsyres.2021.106614_bib0200","first-page":"265","article-title":"Antibiotic allergy in systemic lupus erythematosus: a case-control study","volume":"19","author":"Petri","year":"1992","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2021.106614_bib0205","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/cpt.1004","article-title":"Clinical pharmacogenetics implementation consortium guideline for HLA genotype and use of carbamazepine and oxcarbazepine: 2017 update","volume":"103","author":"Phillips","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106614_bib0210","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"year":"2021","series-title":"Drug Allergies","author":"The World Allergy Organization (WAO)","key":"10.1016\/j.eplepsyres.2021.106614_bib0215"},{"issue":"6","key":"10.1016\/j.eplepsyres.2021.106614_bib0220","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40266-017-0465-7","article-title":"Antiepileptic drug treatment in community-dwelling older patients with epilepsy: a retrospective observational study of old- versus new-generation antiepileptic drugs","volume":"34","author":"Theitler","year":"2017","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.eplepsyres.2021.106614_bib0225","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.eplepsyres.2011.02.005","article-title":"Influence of chemical structure on skin reactions induced by antiepileptic drugs--the role of the aromatic ring","volume":"94","author":"Wang","year":"2011","journal-title":"Epilepsy Res."},{"issue":"7","key":"10.1016\/j.eplepsyres.2021.106614_bib0230","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.clineuro.2012.01.019","article-title":"Antiepileptic drug-induced skin reactions: a retrospective study and analysis in 3793 Chinese patients with epilepsy","volume":"114","author":"Wang","year":"2012","journal-title":"Clin. Neurol. Neurosurg."},{"key":"10.1016\/j.eplepsyres.2021.106614_bib0235","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.eplepsyres.2018.07.011","article-title":"Antiepileptic drug prescription in Dutch children from 2006-2014 using pharmacy-dispensing data","volume":"146","author":"Weijenberg","year":"2018","journal-title":"Epilepsy Res."},{"issue":"5","key":"10.1016\/j.eplepsyres.2021.106614_bib0240","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40258-019-00487-2","article-title":"General trends in prices and prescription patterns of anticonvulsants in Germany between 2000 and 2017: analysis of national and cohort-based data","volume":"17","author":"Willems","year":"2019","journal-title":"Appl. Health Econ. Health Policy"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112100067X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092012112100067X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:44:20Z","timestamp":1760276660000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092012112100067X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":48,"alternative-id":["S092012112100067X"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106614","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics of adverse drug reactions associated with antiepileptics at a tertiary children\u2019s hospital in Japan: A retrospective observational cohort study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2021.106614","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106614"}}